Probody therapeutics for targeting antibodies to diseased tissue

Expert Opin Biol Ther. 2014 Aug;14(8):1049-53. doi: 10.1517/14712598.2014.920814. Epub 2014 May 20.

Abstract

Probodies are proteolytically activated antibodies engineered to remain inert until activated locally in diseased tissue. In principle, any therapeutic antibody can be converted into Probody™ form. In this perspective, we highlight the emerging therapeutic potential of the Probody approach in the form of conventional IgG-based Probodies as well as in the form of 'empowered Probody' formats such as Probody-drug conjugates.

Keywords: EGFR; Jagged; antibody; antibody–drug conjugate; bispecific antibody; chimeric antigen receptor – T cells; probody; protease.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Antibodies, Bispecific / therapeutic use*
  • Antigens / immunology
  • Humans
  • Immunoconjugates / chemistry
  • Immunoconjugates / therapeutic use*
  • Immunoglobulin G / metabolism
  • Immunoglobulin G / therapeutic use
  • Molecular Targeted Therapy / methods*
  • Prodrugs / metabolism
  • Prodrugs / therapeutic use*
  • Protein Engineering

Substances

  • Antibodies, Bispecific
  • Antigens
  • Immunoconjugates
  • Immunoglobulin G
  • Prodrugs